Accendra Health, Inc. ACH
0.71
(0.02)
(2.74%)
as of 25 Sep
- Market cap
- $59.2M
- P/E
- 0.0×
Follow ACH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.48 | 0.08 | 0.06 | 0.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.15) | 3.16 | (3.48) | (10.09) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.17 | 0.72 | 0.71 | 0.96 | |
EV/EBITDA |
7.89 | 8.20 | 7.52 | 8.95 | |
EV/Operating CF |
(24.79) | (19.48) | (16.61) | (14.16) | |
EV/FCF |
(8.81) | (8.81) | (12.52) | (12.11) | |
Quick Ratio |
0.10 | 0.40 | 0.37 | 0.19 | |
Current Ratio |
0.86 | 0.58 | 0.49 | 0.41 | |
Net Debt/EBITDA |
8.99 | (31.79) | 22.40 | 55.99 | |
Debt/Assets |
52.41% | 83.61% | 87.05% | 81.52% | |
Debt/Equity |
(4.92) | (4.45) | (4.53) | (3.12) | |
Asset Turnover |
0.17 | 0.78 | 0.75 | 0.85 | |
Operating CF/Net income |
1.15 | (1.21) | 7.74 | 0.29 | |
Capex/Depreciation |
(0.32) | (0.20) | 0.87 | (0.51) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
38.13% | 38.30% | 40.66% | 39.72% | |
Intangible Assets out of Total Assets |
0.35 | 0.56 | 0.55 | 0.62 | |
Share Based Compensation of Revenue |
1.15% | (0.63%) | 0.49% | 0.65% | |
Graham Net Nets |
(6.29) | (10.98) | (13.15) | (9.10) | |
Graham Number |
46.64 | 43.90 | 43.84 | 25.14 | |
Earnings Yield |
(362.50%) | (510.36%) | (616.23%) | (114.33%) | |
Free Cash Flow Yield |
(75.05%) | (104.57%) | (88.94%) | (80.41%) | |
Revenue per Share |
9.02 | 9.22 | 8.21 | 8.00 | |
Operating CF per Share |
(2.23) | 0.89 | (0.66) | (0.34) | |
Capex per Share |
(0.86) | 0.20 | 0.71 | (0.43) | |
Free Cash Flow per Share |
(3.09) | 1.09 | 0.05 | (0.77) | |
Cash per Share |
0.42 | 3.67 | 4.41 | 0.10 | |
Shareholders Equity per Share |
(5.56) | (5.99) | (6.08) | (7.18) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(5.56) | (5.99) | (6.08) | (7.18) | |
Free Cash Flow |
(238.90) | 83.50 | 3.85 | (59.35) | |
Working Capital |
(334.29) | (399.20) | (614.60) | (394.77) | |
Capital Expenditures |
(66.38) | 15.31 | 53.93 | (33.34) | |
Net Current Asset Value |
(2,334.06) | (2,364.87) | (2,292.25) | (2,386.90) | |
EV/EBIT |
0.00 | 72.22 | 78.27 | 87.01 | |
Capex to Sales |
0.10 | (0.02) | (0.09) | 0.05 | |
Net Profit Margin |
(21.55%) | (7.94%) | (1.03%) | (14.52%) | |
Price to Operating Income |
0.00 | 7.84 | 7.03 | 8.94 | |
| Other line items | |||||
Average Receivables |
432.20 | 157.09 | 341.94 | 158.23 | |
Average Payables |
838.87 | 361.75 | 877.78 | 354.92 | |
Average Inventory |
653.15 | 71.01 | 736.91 | 71.29 | |
Average Assets |
4,558.75 | 3,553.96 | 3,636.20 | 3,130.98 | |
Average Common Equity |
222.54 | 62.69 | 53.11 | (415.97) |
Columns are period end dates